Strategies for the Modification of Vaccinia Virus towards a Better Vaccine Vector

Abstract

Vaccinia virus (VACV) confers cross-protective immunity against variola virus, the causative agent of smallpox, and has therefore been extensively exploited as a preventive vaccine. Despite the global eradication of smallpox in the 1980s, research efforts involving VACV have continued due to the potential threat of variola virus being used as a bioweapon, which poses grave risks to human health. VACV has emerged as a promising viral vector for vaccine development beyond the traditional application of VACV in smallpox prophylaxis, which has been attributed to its capacity for efficient foreign gene expression. Leveraging strategies, such as serial passage in alternative hosts and genetic engineering techniques, have generated highly attenuated VACV vaccine vectors by deleting specific viral genes, most notably those encoding immunomodulatory proteins. The recent emergence of pathogenic orthopoxvirus outbreaks, exemplified by monkeypox, has reignited scientific interest in VACV research. This review delineates the commonly targeted viral genes for attenuation during VACV vector modification and provides an overview of the progress in VACV-vectored vaccine development.

Keywords

Vaccinia virus / Monkeypox / Smallpox / Attenuated vaccine vector

References

[1] Jacobs BL, Langland JO, Kibler KV, Denzler KL, White SD, Holechek SA, et al. Vaccinia virus vaccines: past, present and future. Antiviral Res. 2009; 84(1): 1-13.

[2] Esposito JJ, Sammons SA, Frace AM, Osborne JD, Olsen-Rasmussen M, Zhang M, et al. Genome sequence diversity and clues to the evolution of variola (smallpox) virus. Science. 2006; 313(5788): 807-812.

[3] Barquet N, Domingo P. Smallpox: the triumph over the most terrible of the ministers of death. Ann Intern Med 1997; 127(8 Pt 1): 635-642.

[4] Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent). 2005; 18(1): 21-25.

[5] Wear DJ. Smallpox: the greatest killer: smallpox in history. JAMA. 2003; 289(9): 1171-1173.

[6] Kozlov M. Monkeypox goes global: why scientists are on alert. Nature. 2022; 606(7912): 15-16.

[7] Babkin IV, Babkina IN. The origin of the variola virus. Viruses. 2015; 7(3): 1100-1112.

[8] Breman JG, Henderson DA. Poxvirus dilemmas——monkeypox, smallpox, and biologic terrorism. N Engl J Med. 1998; 339(8): 556-559.

[9] Rotz LD, Dotson DA, Damon IK, Becher JA. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm Rep. 2001; 50(RR-10): 1-25; quiz CE21-27.

[10] Strassburg MA. The global eradication of smallpox. Am J Infect Control. 1982; 10(2): 53-59.

[11] Wehrle PF. A reality in our time——certification of the global eradication of smallpox. J Infect Dis. 1980; 142(4): 636-638.

[12] Sánchez-Sampedro L, Perdiguero B, Mejías-Pérez E, García-Arriaza J, Di Pilato M, Esteban M. The evolution of poxvirus vaccines. Viruses. 2015; 7(4): 1726-1803.

[13] Drexler I, Heller K, Wahren B, Erfle V, Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol. 1998; 79(Pt 2): 347-352.

[14] Antoine G, Scheiflinger F, Dorner F, Falkner FG . The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology. 1998; 244(2): 365-396.

[15] Monath TP, McCarthy K, Bedford P, Johnson CT, Nichols R, Yoksan S, et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine. 2002; 20(7-8): 1004-1018.

[16] Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, Cox WI, et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology. 1992; 188(1): 217-232.

[17] Gubser C, Hué S, Kellam P, Smith GL. Poxvirus genomes: a phylogenetic analysis. J Gen Virol. 2004; 85(Pt 1): 105-117.

[18] Tulman ER, Delhon G, Afonso CL, Lu Z, Zsak L, Sandybaev NT, et al. Genome of horsepox virus. J Virol. 2006; 80(18): 9244-9258.

[19] Moss B. Smallpox vaccines: targets of protective immunity. Immunol Rev. 2011; 239(1): 8-26.

[20] Wilkinson LJMH. Derrick Baxby Jenner’s smallpox vaccine. The riddle of vaccinia virus and its origin . London: Heinemann Educational Books; 1982:xiv, 214, 8vo, illus.. £8.50. 26, 94-95.

[21] Alexander TA. Development of methodology based on commercialized SERS-active substrates for rapid discrimination of Poxviridae virions. Anal Chem. 2008; 80(8): 2817-2825.

[22] Guo ZS, Bartlett DL. Vaccinia as a vector for gene delivery. Expert Opin Biol Ther. 2004; 4(6): 901-917.

[23] Smittkoppor——utrotning av en myt [Smallpox——eradication of a myth]. Lakartidningen. 1989; 86(14): 1290.

[24] Baroudy BM, Venkatesan S, Moss B. Incompletely base-paired flip-flop terminal loops link the two DNA strands of the vaccinia virus genome into one uninterrupted polynucleotide chain. Cell. 1982; 28(2): 315-324.

[25] Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A. 1996; 93(21): 11341-11348.

[26] Guerra S, López-Fernández LA, Conde R, Pascual-Montano A, Harshman K, Esteban M. Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells. J Virol. 2004; 78(11): 5820-5834.

[27] Yang Z, Bruno DP, Martens CA, Porcella SF, Moss B. Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing. Proc Natl Acad Sci U S A. 2010; 107(25): 11513-11518.

[28] Forterre P. The two ages of the RNA world, and the transition to the DNA world: a story of viruses and cells. Biochimie. 2005; 87(9-10): 793-803.

[29] Moss B. Poxvirus DNA replication. Cold Spring Harb Perspect Biol. 2013; 5(9): a010199.

[30] Moss B. Membrane fusion during poxvirus entry. Semin Cell Dev Biol. 2016; 60: 89-96.

[31] Schmidt FI, Bleck CK, Mercer J. Poxvirus host cell entry. Curr Opin Virol. 2012; 2(1): 20-27.

[32] Greseth MD, Traktman P. The life cycle of the vaccinia virus genome. Annu Rev Virol. 2022; 9(1): 239-259.

[33] Roberts KL, Smith GL. Vaccinia virus morphogenesis and dissemination. Trends Microbiol. 2008; 16(10): 472-479.

[34] Smith GL, Vanderplasschen A, Law M. The formation and function of extracellular enveloped vaccinia virus. J Gen Virol. 2002; 83(Pt 12): 2915-2931.

[35] Benhnia MR, McCausland MM, Moyron J, Laudenslager J, Granger S, Rickert S, et al. Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J Virol. 2009; 83(3): 1201-1215.

[36] Reeves PM, Smith SK, Olson VA, Thorne SH, Bornmann W, Damon IK, et al. Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases. J Virol. 2011; 85(1): 21-31.

[37] Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID, et al. Smallpox and its eradication / F. Fenner.. [et al.] . Geneva: World Health Organization; 1988; 1371-1406.

[38] Esparza J, Lederman S, Nitsche A, Damaso CR. Early smallpox vaccine manufacturing in the United States: introduction of the “animal vaccine” in 1870, establishment of “vaccine farms”, and the beginnings of the vaccine industry. Vaccine. 2020; 38(30): 4773-4779.

[39] Esparza J, Nitsche A, Damaso CR. Beyond the myths: novel findings for old paradigms in the history of the smallpox vaccine. PLoS Pathog. 2018; 14(7): e1007082.

[40] Willis NJ. Edward Jenner and the eradication of smallpox. Scott Med J. 1997; 42(4): 118-121.

[41] Jenson AB, Ghim SJ, Sundberg JP. An inquiry into the causes and effects of the variolae (or Cow-pox. 1798). Exp Dermatol. 2016; 25(3): 178-180.

[42] Rosenthal SR, Merchlinsky M, Kleppinger C, Goldenthal KL. Developing new smallpox vaccines. Emerg Infect Dis. 2001; 7(6): 920-926.

[43] Poland GA, Grabenstein JD, Neff JM. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine. 2005; 23(17-18): 2078-2081.

[44] Qin L, Upton C, Hazes B, Evans DH. Genomic analysis of the vaccinia virus strain variants found in Dryvax vaccine. J Virol. 2011; 85(24): 13049-13060.

[45] Ferrier-Rembert A, Drillien R, Meignier B, Garin D, Crance JM . Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate. Vaccine. 2007; 25(49): 8290-8297.

[46] Kim SH, Yeo SG, Jang HC, Park WB, Lee CS, Lee KD, et al. Clinical responses to smallpox vaccine in vaccinia-naive and previously vaccinated populations: undiluted and diluted Lancy-Vaxina vaccine in a single-blind, randomized, prospective trial. J Infect Dis. 2005; 192(6): 1066-1070.

[47] De Cock KM. The eradication of smallpox: Edward Jenner and the first and only eradication of a human infectious disease. Nat Med. 2001; 7(1): 15-16.

[48] Plotkin SA. Vaccines: past, present and future. Nat Med. 2005; 11(Suppl 4): S5-11.

[49] Greenberg RN, Kennedy JS, Clanton DJ, Plummer EA, Hague L, Cruz J, et al. Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial. Lancet. 2005; 365(9457): 398-409.

[50] Downie AW, McCarthy K. The antibody response in man following infection with viruses of the pox group. III. Antibody response in smallpox. J Hyg (Lond). 1958; 56(4): 479-487.

[51] Greenberg RN, Kennedy JS. ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin Investig Drugs. 2008; 17(4): 555-564.

[52] Frey SE, Couch RB, Tacket CO, Treanor JJ, Wolff M, Newman FK, et al. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med. 2002; 346(17): 1265-1274.

[53] Parrino J, Graham BS. Smallpox vaccines: past, present, and future. J Allergy Clin Immunol. 2006; 118(6): 1320-1326.

[54] Kennedy JS, Gurwith M, Dekker CL, Frey SE, Edwards KM, Kenner J, et al. Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults. J Infect Dis. 2011; 204(9): 1395-1402.

[55] Faix DJ, Gordon DM, Perry LN, Raymond-Loher I, Tati N, Lin G, et al. Prospective safety surveillance study of ACAM2000 smallpox vaccine in deploying military personnel. Vaccine. 2020; 38(46): 7323-7330.

[56] Gessain A, Nakoune E, Yazdanpanah Y. Monkeypox. N Engl J Med. 2022; 387(19): 1783-1793.

[57] Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol. 1991; 72 (Pt 5): 1031-1038.

[58] Volz A, Sutter G. Modified vaccinia virus Ankara: history, value in basic research, and current perspectives for vaccine development. Adv Virus Res. 2017; 97: 187-243.

[59] Blanchard TJ, Alcami A, Andrea P, Smith GL. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol. 1998; 79(Pt 5): 1159-1167.

[60] Sutter G, Moss B. Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus. Dev Biol Stand. 1995; 84: 195-200.

[61] Stittelaar KJ, Wyatt LS, de Swart RL, Vos HW, Groen J, van Amerongen G, et al. Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J Virol. 2000; 74(9): 4236-4243.

[62] Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature. 2004; 428(6979): 182-185.

[63] Earl PL, Americo JL, Wyatt LS, Espenshade O, Bassler J, Gong K, et al. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci U S A. 2008; 105(31): 10889-10894.

[64] Cosma A, Nagaraj R, Bühler S, Hinkula J, Busch DH, Sutter G, et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 2003; 22(1): 21-29.

[65] Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis. 2011; 203(5): 610-619.

[66] Gómez CE, Perdiguero B, García-Arriaza J, Cepeda V, Sánchez-Sorzano CÓ, Mothe B, et al. A phase I randomized therapeutic MVA-B vaccination improves the magnitude and quality of the T cell immune responses in HIV-1-infected subjects on HAART. PLoS One. 2015; 10(11): e0141456.

[67] Mothe B, Climent N, Plana M, Rosàs M, Jiménez JL, Muñoz-Fernández M, et al. Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. J Antimicrob Chemother. 2015; 70(6): 1833-1842.

[68] Overton ET, Stapleton J, Frank I, Hassler S, Goepfert PA, Barker D, et al. Safety and immunogenicity of modified vaccinia Ankara-Bavarian nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-infected individuals: an open-label, controlled clinical phase II trial. Open Forum Infect Dis. 2015; 2(2): ofv040.

[69] Nave L, Margalit I, Tau N, Cohen I, Yelin D, Lienert F, et al. Immunogenicity and safety of modified vaccinia Ankara (MVA) vaccine - a systematic review and meta-analysis of randomized controlled trials. Vaccines (Basel). 2023; 11(9): 1410.

[70] Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M. LC16m8: an attenuated smallpox vaccine. Vaccine. 2006; 24(47-48): 7009-7022.

[71] Saijo M, Ami Y, Suzaki Y, Nagata N, Iwata N, Hasegawa H, et al. LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox. J Virol. 2006; 80(11): 5179-5188.

[72] Kennedy JS, Greenberg RN. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines. 2009; 8(1): 13-24.

[73] Tagaya I, Kitamura T, Sano Y. A new mutant of dermovaccinia virus. Nature. 1961; 192: 381-382.

[74] Ishii K, Ueda Y, Matsuo K, Matsuura Y, Kitamura T, Kato K, et al. Structural analysis of vaccinia virus DIs strain: application as a new replication-deficient viral vector. Virology. 2002; 302(2): 433-444.

[75] Terajima M, Urban SL, Leporati AM. The N-terminus of vaccinia virus host range protein C7L is essential for function. Virus Genes. 2013; 46(1): 20-27.

[76] Meng X, Jiang C, Arsenio J, Dick K, Cao J, Xiang Y. Vaccinia virus K1L and C7L inhibit antiviral activities induced by type I interferons. J Virol. 2009; 83(20): 10627-10636.

[77] Lim H, In HJ, Kim YJ, Jang S, Lee YH, Kim SH, et al. Development of an attenuated smallpox vaccine candidate: the KVAC103 strain. Vaccine. 2021; 39(36): 5214-5223.

[78] Park DB, Ahn BE, Son H, Lee YR, Kim YR, Jo SK, et al. Construction of a bivalent vaccine against anthrax and smallpox using the attenuated vaccinia virus KVAC103. BMC Microbiol. 2021; 21(1): 76.

[79] Haller SL, Peng C, McFadden G, Rothenburg S. Poxviruses and the evolution of host range and virulence. Infect Genet Evol. 2014; 21: 15-40.

[80] Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A. 1996; 93(21): 11349-11353.

[81] Tartaglia J, Cox WI, Taylor J, Perkus M, Riviere M, Meignier B, et al. Highly attenuated poxvirus vectors. AIDS Res Hum Retroviruses. 1992; 8(8): 1445-1447.

[82] Nájera JL, Gómez CE, Domingo-Gil E, Gherardi MM, Esteban M. Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J Virol. 2006; 80(12): 6033-6047.

[83] Paoletti E, Tartaglia J, Taylor J. Safe and effective poxvirus vectors——NYVAC and ALVAC. Dev Biol Stand. 1994; 82: 65-69.

[84] Ruan L, Zhu J, Lou T, Lu R. Non-replicating vaccinia virus Tiantan. China ZL200610056800.0 [P/OL], 2006.

[85] Gómez CE, Nájera JL, Krupa M, Esteban M. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther. 2008; 8(2): 97-120.

[86] Eldi P, Cooper TH, Prow NA, Liu L, Heinemann GK, Zhang VJ, et al. The vaccinia-based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses. Immunol Cell Biol. 2022; 100(4): 250-266.

[87] Prow NA, Liu L, McCarthy MK, Walters K, Kalkeri R, Geiger J, et al. The vaccinia virus based Sementis Copenhagen Vector vaccine against Zika and chikungunya is immunogenic in non-human primates. NPJ Vaccines. 2020; 5(1): 44.

[88] Prow NA, Liu L, Nakayama E, Cooper TH, Yan K, Eldi P, et al. A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses. Nat Commun. 2018; 9(1): 1230.

[89] Zhao Y, Zhao L, Huang P, Ren J, Zhang P, Tian H, et al. Non-replicating vaccinia virus TianTan strain (NTV) translation arrest of viral late protein synthesis associated with anti-viral host factor SAMD9. Front Cell Infect Microbiol. 2020; 10: 116.

[90] Tian H, Ren J, Huang W, Fan J, Zhao L, Ruan L. Construction of non——replicating recombinant vaccinia virus expressing human papillomavirus 16E6/E7 fusion protein and study of its immunogenicity and antitumor response. [Bing du xue bao] Chinese journal of virology. 2006; 22(5): 358-363.

[91] Zhan Y, Deng Y, Huang B, Song Q, Wang W, Yang Y, et al. Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates. Vaccine. 2019; 37(15): 2122-2130.

[92] Gilbert SC . Clinical development of modified vaccinia virus Ankara vaccines. Vaccine. 2013; 31(39): 4241-4246.

[93] Gómez CE, Perdiguero B, García-Arriaza J, Esteban M. Clinical applications of attenuated MVA poxvirus strain. Expert Rev Vaccines. 2013; 12(12): 1395-1416.

[94] Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579(7798): 265-269.

[95] Chiuppesi F, Nguyen VH, Park Y, Contreras H, Karpinski V, Faircloth K, et al. Synthetic multiantigen MVA vaccine COHo4S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates. NPJ Vaccines. 2022; 7(1): 7.

[96] Chiuppesi F, Salazar MD, Contreras H, Nguyen VH, Martinez J, Park Y, et al. Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform. Nat Commun. 2020; 11(1): 6121.

[97] Wussow F, Kha M, Faircloth K, Nguyen VH, Iniguez A, Martinez J, et al. COHo4S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants. iScience. 2022; 25(6): 104457.

[98] García-Arriaza J, Garaigorta U, Pérez P, Lázaro-Frías A, Zamora C, Gastaminza P, et al. COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice. J Virol. 2021; 95(7): e02260-20.

[99] Pérez P, Astorgano D, Albericio G, Flores S, Sánchez-Cordón PJ, Luczkowiak J, et al. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection. Front Immunol. 2022; 13: 995235.

[100] Bošnjak B, Odak I, Barros-Martins J, Sandrock I, Hammerschmidt SI, Permanyer M, et al. Intranasal delivery of MVA vector vaccine induces effective pulmonary immunity against SARS-CoV-2 in rodents. Front Immunol. 2021; 12: 772240.

[101] Meseda CA, Stauft CB, Selvaraj P, Lien CZ, Pedro C, Nuñez IA, et al. MVA vector expression of SARS-CoV-2 spike protein and protection of adult Syrian hamsters against SARS-CoV-2 challenge. NPJ Vaccines. 2021; 6(1): 145.

[102] Routhu NK, Gangadhara S, Lai L, Davis-Gardner ME, Floyd K, Shiferaw A, et al. A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 delta infection. Sci Immunol. 2022; 7(72): eabo0226.

[103] Lázaro-Frías A, Pérez P, Zamora C, Sánchez-Cordón PJ, Guzmán M, Luczkowiak J, et al. Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice. NPJ Vaccines. 2022; 7(1): 17.

[104] Boudewijns R, Pérez P, Lázaro-Frías A, Van Looveren D, Vercruysse T, Thibaut HJ, et al. MVA-CoV2-S vaccine candidate neutralizes distinct variants of concern and protects against SARS-CoV-2 infection in hamsters. Front Immunol 2022; 13: 845969.

[105] Mooij P, García-Arriaza J, Pérez P, Lázaro-Frías A, Verstrepen BE, Böszörményi KP, et al. Poxvirus MVA expressing SARS-CoV-2 S protein induces robust immunity and protects rhesus macaques from SARS-CoV-2. Front Immunol. 2022; 13: 845887.

[106] Tapia MD, Sow SO, Lyke KE, Haidara FC, Diallo F, Doumbia M, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016; 16(1): 31-42.

[107] Malherbe DC, Domi A, Hauser MJ, Meyer M, Gunn BM, Alter G, et al. Modified vaccinia Ankara vaccine expressing Marburg virus-like particles protects guinea pigs from lethal Marburg virus infection. NPJ Vaccines. 2020; 5(1): 78.

[108] Alharbi NK, Aljamaan F, Aljabi HA, Alenazi MW, Albalawi H, Almasoud A, et al. Immunogenicity of high-dose MVA-based MERS vaccine candidate in mice and camels. Vaccines (Basel). 2022; 10(8): 1330.

[109] Gómez CE, Perdiguero B, Garcia-Arriaza J, Esteban M. Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother. 2012; 8(9): 1192-1207.

[110] García-Arriaza J, Nájera JL, Gómez CE, Tewabe N, Sorzano CO, Calandra T, et al. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS One. 2011; 6(8): e24244.

[111] Pérez P, Marín MQ, Lázaro-Frías A, Sorzano CÓS, Gómez CE, Esteban M, et al. Deletion of vaccinia virus A40R gene improves the immunogenicity of the HIV-1 vaccine candidate MVA-B. Vaccines (Basel). 2020; 8(1): 70.

[112] Jordan R, Leeds JM, Tyavanagimatt S, Hruby DE. Development of ST-246® for treatment of poxvirus infections. Viruses. 2010; 2(11): 2409-2435.

[113] Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J Virol. 2005; 79(20): 13139-13149.

[114] Grosenbach DW, Jordan R, Hruby DE. Development of the small-molecule antiviral ST-246 as a smallpox therapeutic. Future Virol. 2011; 6(5): 653-671.

[115] Hiller G, Eibl H, Weber K. Characterization of intracellular and extracellular vaccinia virus variants: N1-isonicotinoyl-N2-3-methyl-4-chlorobenzoylhydrazine interferes with cytoplasmic virus dissemination and release. J Virol. 1981; 39(3): 903-913.

[116] Bryk P, Brewer MG, Ward BM. Vaccinia virus phospholipase protein F13 promotes rapid entry of extracellular virions into cells. J Virol. 2018; 92(11): e02154-17.

[117] Vliegen I, Yang G, Hruby D, Jordan R, Neyts J. Deletion of the vaccinia virus F13L gene results in a highly attenuated virus that mounts a protective immune response against subsequent vaccinia virus challenge. Antiviral Res. 2012; 93(1): 160-166.

[118] Blasco R, Moss B. Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein. J Virol. 1991; 65(11): 5910-5920.

[119] Engelstad M, Smith GL. The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence. Virology. 1993; 194(2): 627-637.

[120] Grosenbach DW, Hansen SG, Hruby DE. Identification and analysis of vaccinia virus palmitylproteins. Virology. 2000; 275(1): 193-206.

[121] Grosenbach DW, Ulaeto DO, Hruby DE. Palmitylation of the vaccinia virus 37-kDa major envelope antigen. Identification of a conserved acceptor motif and biological relevance. J Biol Chem. 1997; 272(3): 1956-1964.

[122] Ward BM, Moss B. Golgi network targeting and plasma membrane internalization signals in vaccinia virus B5R envelope protein. J Virol. 2000; 74(8): 3771-3780.

[123] Rodger G, Smith GL . Replacing the SCR domains of vaccinia virus protein B5R with EGFP causes a reduction in plaque size and actin tail formation but enveloped virions are still transported to the cell surface. J Gen Virol. 2002; 83(Pt 2): 323-332.

[124] Horsington J, Lynn H, Turnbull L, Cheng D, Braet F, Diefenbach RJ, et al. A36-dependent actin filament nucleation promotes release of vaccinia virus. PLoS Pathog. 2013; 9(3): e1003239.

[125] Katz E, Wolffe E, Moss B. Identification of second-site mutations that enhance release and spread of vaccinia virus. J Virol. 2002; 76(22): 11637-11644.

[126] Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021; 6(1): 53.

[127] Shirley JL, de Jong YP, Terhorst C, Herzog RW . Immune responses to viral gene therapy vectors. Mol Ther. 2020; 28(3): 709-722.

[128] Yakubitskiy SN, Kolosova IV, Maksyutov RA, Shchelkunov SN. Attenuation of vaccinia virus. Acta Naturae. 2015; 7(4): 113-121.

[129] Wang Y, Kan S, Du S, Qi Y, Wang J, Liu L, et al. Characterization of an attenuated TE3L-deficient vaccinia virus Tian Tan strain. Antiviral Res. 2012; 96(3): 324-332.

[130] Chang HW, Watson JC, Jacobs BL. The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase. Proc Natl Acad Sci U S A. 1992; 89(11): 4825-4829.

[131] Brandt TA, Jacobs BL. Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model. J Virol. 2001; 75(2): 850-856.

[132] Romano PR, Zhang F, Tan SL, Garcia-Barrio MT, Katze MG, Dever TE, et al. Inhibition of double-stranded RNA-dependent protein kinase PKR by vaccinia virus E3: role of complex formation and the E3 N-terminal domain. Mol Cell Biol. 1998; 18(12): 7304-7316.

[133] Bowie A, Kiss-Toth E, Symons JA, Smith GL, Dower SK, O’Neill LA. A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc Natl Acad Sci U S A. 2000; 97(18): 10162-10167.

[134] Stack J, Haga IR, Schröder M, Bartlett NW, Maloney G, Reading PC, et al. Vaccinia virus protein A46R targets multiple toll-like-interleukin-1 receptor adaptors and contributes to virulence. J Exp Med. 2005; 201(6): 1007-1018.

[135] Harte MT, Haga IR, Maloney G, Gray P, Reading PC, Bartlett NW, et al. The poxvirus protein A52R targets toll-like receptor signaling complexes to suppress host defense. J Exp Med. 2003; 197(3): 343-351.

[136] Maloney G, Schröder M, Bowie AG. Vaccinia virus protein A52R activates p38 mitogen-activated protein kinase and potentiates lipopolysaccharide-induced interleukin-10. J Biol Chem. 2005; 280(35): 30838-30844.

[137] DiPerna G, Stack J, Bowie AG, Boyd A, Kotwal G, Zhang Z, et al. Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors. J Biol Chem. 2004; 279(35): 36570-36578.

[138] Bartlett N, Symons JA, Tscharke DC, Smith GL. The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence. J Gen Virol 2002; 83(Pt 8): 1965-1976.

[139] Cooray S, Bahar MW, Abrescia NGA, McVey CE, Bartlett NW, Chen RA, et al. Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. J Gen Virol 2007; 88(Pt 6): 1656-1666.

[140] Maluquer de Motes C, Cooray S, Ren H, Almeida GM, McGourty K, Bahar MW, et al. Inhibition of apoptosis and NF-κB activation by vaccinia protein N1 occur via distinct binding surfaces and make different contributions to virulence. PLoS Pathog. 2011; 7(12): e1002430.

[141] Shmeleva EV, Syafiq D, Moldoveanu AL, Ferguson BJ, Smith GL. Suppression of innate immunity by the vaccinia virus protein N1 promotes skin microbiota expansion and increased immune infiltration following vaccination. J Gen Virol. 2022; 103(11): 10.1099/jgv.0.001814.

[142] Law M, Smith GL. Studying the binding and entry of the intracellular and extracellular enveloped forms of vaccinia virus. Methods Mol Biol. 2004; 269: 187-204.

[143] Zhang Z, Abrahams MR, Hunt LA, Suttles J, Marshall W, Lahiri DK, et al. The vaccinia virus N1L protein influences cytokine secretion in vitro after infection. Ann N Y Acad Sci. 2005; 1056: 69-86.

[144] Child SJ, Palumbo GJ, Buller RM, Hruby DE. Insertional inactivation of the large subunit of ribonucleotide reductase encoded by vaccinia virus is associated with reduced virulence in vivo. Virology. 1990; 174(2): 625-629.

[145] Smith GL, de Carlos A, Chan YS. Vaccinia virus encodes a thymidylate kinase gene: sequence and transcriptional mapping. Nucleic Acids Res. 1989; 17(19): 7581-7590.

[146] Amegadzie BY, Sisler JR, Moss B. Frame-shift mutations within the vaccinia virus A-type inclusion protein gene. Virology. 1992; 186(2): 777-782.

[147] Johnson GP, Goebel SJ, Paoletti E. An update on the vaccinia virus genome. Virology. 1993; 196(2): 381-401.

[148] Sumner RP, Ren H, Ferguson BJ, Smith GL. Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators. Vaccine. 2016; 34(40): 4827-4834.

[149] Mossman K, Upton C, Buller RM, McFadden G. Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins. Virology. 1995; 208(2): 762-769.

[150] Verardi PH, Jones LA, Aziz FH, Ahmad S, Yilma TD. Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated in vivo without a concomitant reduction in immunogenicity. J Virol. 2001; 75(1): 11-18.

[151] Dénes B, Gridley DS, Fodor N, Takátsy Z, Timiryasova TM, Fodor I. Attenuation of a vaccine strain of vaccinia virus via inactivation of interferon viroceptor. J Gene Med. 2006; 8(7): 814-823.

[152] Kotwal GJ, Isaacs SN, McKenzie R, Frank MM, Moss B. Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science. 1990; 250(4982): 827-830.

[153] Sahu A, Isaacs SN, Soulika AM, Lambris JD. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway. J Immunol. 1998; 160(11): 5596-5604.

[154] Shchelkunov SN. Orthopoxvirus genes that mediate disease virulence and host tropism. Adv Virol. 2012; 2012: 524743.

[155] Miller CG, Shchelkunov SN, Kotwal GJ. The cowpox virus-encoded homolog of the vaccinia virus complement control protein is an inflammation modulatory protein. Virology. 1997; 229(1): 126-133.

[156] Isaacs SN, Kotwal GJ, Moss B. Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc Natl Acad Sci U S A. 1992; 89(2): 628-632.

[157] Lee MS, Roos JM, McGuigan LC, Smith KA, Cormier N, Cohen LK, et al. Molecular attenuation of vaccinia virus: mutant generation and animal characterization. J Virol. 1992; 66(5): 2617-2630.

[158] Shida H, Hinuma Y, Hatanaka M, Morita M, Kidokoro M, Suzuki K, et al. Effects and virulences of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type I envelope gene. J Virol. 1988; 62(12): 4474-4480.

[159] Buller RM, Smith GL, Cremer K, Notkins AL, Moss B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature. 1985; 317(6040): 813-815.

[160] Taylor G, Stott EJ, Wertz G, Ball A. Comparison of the virulence of wild-type thymidine kinase (tk)-deficient and tk⁺ phenotypes of vaccinia virus recombinants after intranasal inoculation of mice . J Gen Virol. 1991; 72(Pt 1): 125-130.

[161] Meng X, Zhang F, Yan B, Si C, Honda H, Nagamachi A, et al. A paralogous pair of mammalian host restriction factors form a critical host barrier against poxvirus infection. PLoS Pathog. 2018; 14(2): e1006884.

[162] Huang LL, Wu LL, Li X, Liu K, Zhao D, Xie HY. Labeling and single-particle-tracking-based entry mechanism study of vaccinia virus from the Tiantan strain. Anal Chem. 2018; 90(5): 3452-3459.

[163] Schmidt FI, Bleck CK, Helenius A, Mercer J. Vaccinia extracellular virions enter cells by macropinocytosis and acid-activated membrane rupture. EMBO J. 2011; 30(17): 3647-3661.

[164] Moss B. Poxvirus cell entry: how many proteins does it take? Viruses. 2012; 4(5): 688-707.

[165] Bratke KA, McLysaght A, Rothenburg S. A survey of host range genes in poxvirus genomes. Infect Genet Evol. 2013; 14: 406-425.

[166] McFadden G. Poxvirus tropism. Nat Rev Microbiol. 2005; 3(3): 201-213.

[167] Gillard S, Spehner D, Drillien R, Kirn A. Localization and sequence of a vaccinia virus gene required for multiplication in human cells. Proc Natl Acad Sci U S A. 1986; 83(15): 5573-5577.

[168] Perkus ME, Goebel SJ, Davis SW, Johnson GP, Limbach K, Norton EK, et al. Vaccinia virus host range genes. Virology. 1990; 179(1): 276-286.

[169] Hsiao JC, Chung CS, Drillien R, Chang W. The cowpox virus host range gene, CP77, affects phosphorylation of eIF2 alpha and vaccinia viral translation in apoptotic HeLa cells. Virology. 2004; 329(1): 199-212.

[170] Kibler KV, Gomez CE, Perdiguero B, Wong S, Huynh T, Holechek S, et al. Improved NYVAC-based vaccine vectors. PLoS One. 2011; 6(11): e25674.

[171] Meng X, Schoggins J, Rose L, Cao J, Ploss A, Rice CM, et al. C7L family of poxvirus host range genes inhibits antiviral activities induced by type I interferons and interferon regulatory factor 1. J Virol. 2012; 86(8): 4538-4547.

[172] Rothenburg S, Chinchar VG, Dever TE. Characterization of a ranavirus inhibitor of the antiviral protein kinase PKR. BMC Microbiol. 2011; 11: 56.

[173] Bai G, Jia HJ, He XB, Jing ZZ. [Progress on host range factors and their mechanisms of poxvirus]. Bing Du Xue Bao. Chinese. 2013; 29(6): 655-661.

[174] Liu R, Mendez-Rios JD, Peng C, Xiao W, Weisberg AS, Wyatt LS, et al. SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells. PLoS Pathog. 2019; 15(5): e1007710.

[175] Peng C, Moss B. Repair of a previously uncharacterized second host-range gene contributes to full replication of modified vaccinia virus Ankara (MVA) in human cells. Proc Natl Acad Sci U S A. 2020; 117(7): 3759-3767.

[176] Zhu W, Fang Q, Zhuang K, Wang H, Yu W, Zhou J, et al. The attenuation of vaccinia Tian Tan strain by the removal of the viral M1L-K2L genes. J Virol Methods. 2007; 144(1-2): 17-26.

[177] Cooney EL, Collier AC, Greenberg PD, Coombs RW, Zarling J, Arditti DE, et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet. 1991; 337(8741): 567-572.

[178] Shang Y, Wang M, Xiao G, Wang X, Hou D, Pan K, et al. Construction and rescue of a functional synthetic baculovirus. ACS Synth Biol. 2017; 6(7): 1393-1402.

[179] Thi Nhu Thao T, Labroussaa F, Ebert N, V’Kovski P, Stalder H, Portmann J, et al. Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform. Nature. 2020; 582(7813): 561-565.

[180] Xiao H, Hu H, Guo Y, Li J, Wen L, Zeng WB, et al. Construction and characterization of a synthesized herpes simplex virus H129-Syn-G2. Virol Sin. 2023; 38(3): 373-379.

[181] Noyce RS, Lederman S, Evans DH. Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments. PLoS One. 2018; 13(1): e0188453.

[182] Iqbal S, Blenner M, Alexander-Bryant A, Larsen J. Polymersomes for therapeutic delivery of protein and nucleic acid macromolecules: from design to therapeutic applications. Biomacromolecules. 2020; 21(4): 1327-1350.

[183] Lam JH, Khan AK, Cornell TA, Chia TW, Dress RJ, Yeow WWW, et al. Polymersomes as stable nanocarriers for a highly immunogenic and durable SARS-CoV-2 spike protein subunit vaccine. ACS Nano. 2021; 15(10): 15754-15770.

[184] Ye T, Jiao Z, Li X, He Z, Li Y, Yang F, et al. Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization. Nature. 2023; 624(7992): 630-638.

[185] Pedersen K, Gilbert AT, Nelson KM, Morgan DP, Davis AJ, VerCauteren KC, et al. Raccoon (Procyon lotor) response to Ontario rabies vaccine baits (ONRAB) in St. Lawrence County, New york, USA. J Wildl Dis. 2019; 55(3): 645-653.

[186] Shuai L, Feng N, Wang X, Ge J, Wen Z, Chen W, et al. Genetically modified rabies virus ERA strain is safe and induces long-lasting protective immune response in dogs after oral vaccination. Antiviral Res. 2015; 121: 9-15.